Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eladynos

- PMLiVE

Amgen’s Repatha unclogs blocked arteries, says study

Looks to boost sales after trial shows clear clinical advantage of PCSK9 inhibitor over statins

- PMLiVE

CHMP recommends Merck & Co’s Lantus biosimilar

Also backs two biosimilar versions of Lilly’s osteoporosis therapy Forteo

- PMLiVE

Amgen wins European approval for Parsabiv

Follows FDA knock-back in August for the chronic kidney disease treatment

Eli Lilly HQ

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients

- PMLiVE

NICE set to knock-back Amgen’s myeloma treatment Kyprolis

Cites uncertainty in clinical and cost-effectiveness analyses

- PMLiVE

Torrid times at Gilead lead to calls for a major M&A deal

HIV portfolio sales down almost 10% to $7.5bn despite strong $533m start for Epclusa

- PMLiVE

Pfizer dropping bococizumab casts shadow over PCSK9 class

US payer resistance and diminishing efficacy prompt decision on would-be blockbuster

Novartis Gehry Building

Novartis says its biosimilar sales should reach $1bn this year

Four-drug portfolio grew by 40% to $262m in the quarter

- PMLiVE

FDA halts study of Teva and Regeneron’s pain drug fasinumab

Firms to redesign phase III trial excluding patients with advanced osteoarthritis after set back

- PMLiVE

CHMP backs Intercept’s rare liver disease drug

Ocaliva on track for EU approval as analysts predict blockbuster sales

Roche Basel Switzerland

AbbVie and Roche’s leukaemia drug venetoclax nears EU market

CHMP grants blood cancer treatment Venclyxto a conditional green light

- PMLiVE

Novartis says migraine prevention drug clears phase III trial

Monthly injection co-developed with Amgen could be launched in 2018

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links